Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20146704 | 0.94 | TAAR1 (0.73) | TAAR1TSHRADRA2AADRA2BADRA2C | |
| SCHEMBL7116263 | 0.92 | TAAR1 (0.70) | TAAR1TSHRADRA2AADRA2BADRA2C | |
| SCHEMBL8571535 | 0.92 | TAAR1 (0.70) | TAAR1TSHRADRA2AADRA2BADRA2C | |
| SCHEMBL6734915 | 0.92 | TAAR1 (0.70) | TAAR1TSHRADRA2AADRA2BADRA2C | |
| SCHEMBL29720358 | 0.89 | TAAR1 (0.59) | TAAR1TSHRADRA2AADRA2BADRA2C | |
| SCHEMBL2030841 | 0.88 | TAAR1 (0.71) | TAAR1TSHRADRA2AADRA2BADRA2C | |
| SCHEMBL6333918 | 0.87 | TAAR1 (0.57) | TAAR1TSHRADRA2AADRA2BADRA2C | |
| SCHEMBL13463911 | 0.85 | — | — | |
| SCHEMBL80666 | 0.85 | — | — | |
| SCHEMBL94727 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115093323-B | Beta-functionalized chiral homoallylic alcohol derivative and preparation method and application thereof | 武汉大学 | 2023-12-22 | — | — | CN | disclosed |
| CN-115093323-A | Beta-functionalized chiral homoallyl alcohol derivative and preparation method and application thereof | 武汉大学 | 2022-09-23 | — | — | CN | disclosed |
| EP-3321291-B1 | CATALYST COMPOSITION COMPRISING NOVEL TRANSITION METAL COMPOUND | LG CHEMICAL LTD (KR) | 2022-05-18 | — | — | EP | disclosed |
| EP-3321291-B1 | CATALYST COMPOSITION COMPRISING NOVEL TRANSITION METAL COMPOUND | LG CHEMICAL LTD (KR) | 2022-05-18 | — | — | EP | disclosed |
| US-10947327-B2 | Catalyst composition including novel transition metal compound | LG CHEM, LTD. | 2021-03-16 | — | — | US | disclosed |
| US-10947327-B2 | Catalyst composition including novel transition metal compound | LG CHEM, LTD. | 2021-03-16 | — | — | US | disclosed |
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180201697-A1 | CATALYST COMPOSITION INCLUDING NOVEL TRANSITION METAL COMPOUND | LG CHEM, LTD. (KR) | 2018-07-19 | — | — | US | disclosed |
| US-20180201697-A1 | CATALYST COMPOSITION INCLUDING NOVEL TRANSITION METAL COMPOUND | LG CHEM, LTD. (KR) | 2018-07-19 | — | — | US | disclosed |
| US-20180201697-A1 | CATALYST COMPOSITION INCLUDING NOVEL TRANSITION METAL COMPOUND | LG CHEM, LTD. (KR) | 2018-07-19 | — | — | US | disclosed |
| EP-3321291-A1 | CATALYST COMPOSITION COMPRISING NOVEL TRANSITION METAL COMPOUND | LG Chem, Ltd. (KR) | 2018-05-16 | — | — | EP | disclosed |
| EP-3321291-A1 | CATALYST COMPOSITION COMPRISING NOVEL TRANSITION METAL COMPOUND | LG Chem, Ltd. (KR) | 2018-05-16 | — | — | EP | disclosed |
| US-20170044130-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2017-02-16 | — | — | US | disclosed |
| US-9512109-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-12-24 | — | — | US | disclosed |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-10-15 | — | — | US | disclosed |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2013-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | TAAR1 1134/4885TSHR 396/4885ADRA2A 36/4885 |
| US-10947327-B2 | Catalyst composition including novel transition metal compound | COG4, MCM4, ZNF436-AS1 | TAAR1 3759/4885TSHR 4773/4885ADRA2A 4800/4885 |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | TAAR1 1098/4885TSHR 405/4885ADRA2A 33/4885 |
| US-20180201697-A1 | CATALYST COMPOSITION INCLUDING NOVEL TRANSITION METAL COMPOUND | COG4, MCM4, ZNF436-AS1 | TAAR1 3759/4885TSHR 4773/4885ADRA2A 4800/4885 |
| US-20170044130-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | TAAR1 1098/4885TSHR 405/4885ADRA2A 33/4885 |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | TAAR1 1134/4885TSHR 396/4885ADRA2A 36/4885 |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | TAAR1 1134/4885TSHR 396/4885ADRA2A 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.